Insurer drug reclassification leads to price spike for patients

Share this article:

Health insurers are shifting expensive drugs into “tier 4” classification, resulting in a price spike for some patients, according to a New York Times report. The tier 4 system already exists in 86% of national Medicare health plans. 

Private health insurers have reclassified a number of drug treatments for serious or chronic disorders, such as multiple sclerosis, rheumatoid arthritis, hemophilia, hepatitis C and some cancers, the Times reports.  In the past, private insurers have typically reserved tier 4 classification for expensive “lifestyle” drugs, such as erectile dysfunction treatments, or biologics, such as HIV treatments.

In some cases, drugs previously available for a fixed co-payment are now requiring patients to pay an average rate of 36% of the total drug cost, according to a Kaiser Family Foundation survey.

Given the expense of some drugs, a percentage of the total drug cost could mean hundreds of dollars for a single 30-day prescription – even when the medication was previously classified under a different tier, and a different payment structure.

Payment structure, or “cost-sharing,” for tier 4 drugs, varies between fixed co-payment and co-insurance rates. “Co-insurance” refers to payment in the form of a percentage of the total drug cost. In 2007, the average co-payment for tier 4 drugs was $71, while the average co-insurance rate was 36%, with the number of workers facing co-payments or co-insurance rates being roughly equal, according to the Kaiser survey.

Three out of four employees receiving health insurance coverage were enrolled in plans with tier 3 or tier 4 classifications, the survey said.

Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.